Company intelligence / Profile preview
Levation Pharma
Tel Aviv, Israellevationpharma.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Levation Pharma is developing a proprietary gel containing an alpha-adrenergic agent to treat acquired blepharoptosis. The company initiated a Phase 1/2 clinical trial in early 2023. The therapy aims to induce mild contraction in the eyelid muscle, improving both function and appearance. No published results from the trial are available as of June 2025.
- Therapeutic areas
- Ophthalmology
- Modalities
- Small moleculeGel-based drug delivery
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Pontifax VenturesPeregrine Ventures
Beyond the preview
Go deeper on Levation Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Levation Pharma.